丹特罗能纠正达利尔病的细胞疾病特征,可能是一种新的治疗方法
Matthew Hunt1, Nuoqi Wang1, Naricha Pupinyo1
1Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden.
EMBO molecular medicine
|July 26, 2024
概括
丹特罗酸盐可以治疗达利尔病 (DD),一种罕见的皮肤疾病. 这项研究表明,在DD模型中,它有助于恢复细胞粘附和平衡,同时减少细胞应激和细胞亡.
科学领域:
- 皮肤病学 皮肤病学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 达里尔病 (DD) 是一种罕见的,严重的阿坎托利性皮肤疾病,由ATP2A2基因突变引起,影响/内分泌网膜ATP酶异型2 (SERCA2).
- 塞尔卡2功能障碍破坏了内细胞网膜 (ER) 平衡,影响细胞功能,目前没有针对DD的向治疗方法.
- 细胞粘附的失调,平衡,ER压力和亡都与DD的发病有关.
研究的目的:
- 调查达里尔病 (DD) 背后的分子机制,并评估丹特 (Dl) 作为潜在的治疗剂.
- 为了确定DD患者皮肤样本中受影响的特定分子通路.
- 在体外DD模型中评估DL在恢复细胞功能和减轻疾病机制方面的有效性.
主要方法:
- 从DD患者的皮肤样本中分析基因表达和分子通路.
- 使用了模拟DD和SERCA2抑制的体外模型.
- 评估了丹特罗林 (Dl) 对ER水平,细胞粘附,ER压力和亡的影响.
主要成果:
- 在DD患者皮肤中确定了下调的细胞粘附和平衡通路,以及上调的ER压力和亡.
- 在DD体外模型中证明,Dl治疗增强了ER的保留,并促进了细胞粘附.
- 观察到Dl显著降低了ER压力和抑制了亡,这表明它对致病机制产生了直接影响.
结论:
- 丹特罗林 (Dl) 有效地向达利尔病 (DD) 中的关键致病机制.
- Dl恢复ER平衡的能力,改善细胞粘附,减少细胞压力表明其作为DD的新疗法治疗的潜力.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
664
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
664
Skeletal Muscle Relaxants: Therapeutic Uses
477
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
477
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Skeletal Muscle Relaxants: Adverse Effects
349
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
349
Depolarizing Blockers: Pharmocokinetics
317
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
317
Classification of Skeletal Muscle Relaxants
2.4K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.4K


